Developer docs
API playgroundTry for free, no card

Search company profiles

Optina Diagnostics

Full company profile

uuid00024e8

Namestring
Optina Diagnostics
Legal namestring
Optina
Websiteurl
optinadx.com
Company typeenum
Private
Founded yearint
2011
Descriptiontext

Optina Diagnostics is a Montreal-based private medical device and diagnostics company developing AI-enabled hyperspectral retinal imaging technology for early detection and management of retinal disease, with a primary focus on Age-Related Macular Degeneration (AMD). Its core offering combines an FDA 510(k)-cleared hyperspectral camera, which captures retinal images in approximately one second, with AI-driven clinical decision analytics designed to detect early and intermediate stage retinal disease, identify patients at high risk of vision impairment, and monitor disease progression and therapeutic response. The company is also extending the platform toward a cerebral amyloid status test for Alzheimer's detection, supported by a grant from the Alzheimer's Drug Discovery Foundation's Diagnostics Accelerator.

Optina sells its hardware-and-software platform through enterprise direct sales to eye care specialists, including ophthalmologists and retina specialists, primarily in the United States, Canada, and Europe, where it is expanding clinical study sites. The revenue model is hardware-centric, anchored on sales of the FDA-cleared camera system bundled with AI analytics software, though pricing is not publicly disclosed and operates on custom quotes. The company is venture capital-backed, having closed a CA$24.8 million Series A in October 2021 led by DigitalDx Ventures with participation from Boehringer Ingelheim Venture Fund, supplementing earlier seed and pre-seed rounds from Canadian and US investors.

The company operates in a large and growing addressable market: an estimated 300 million people are projected to experience moderate to severe vision loss from AMD by 2040, with annual direct healthcare costs of approximately US$100 billion in the US and US$343 billion globally. Optina is led by CEO David Lapointe and co-founder and CFO Chantal Miklosi, with a team in the 11-50 employee range, consistent with a clinical-stage medical device company still building toward scaled commercial deployment.

Short descriptiontext

Optina Diagnostics is a Montreal-based medical device company that combines an FDA 510(k)-cleared hyperspectral retinal camera with AI clinical decision analytics to support early detection and management of Age-Related Macular Degeneration, selling to ophthalmologists and retina specialists.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMontréal, Canada
HQ citystring
Montréal
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
retinal imaging diagnostics, hyperspectral imaging devices, AI clinical decision support, ophthalmic medical devices, macular degeneration detection
Industry2 codes
PRIMARYHLAHAJAB
Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAKAKAE
Retina & Vitreous Specialists
NAICS code1 code
  • Ophthalmic Goods Manufacturing339115
SIC code1 code
  • Optical Instruments & Lenses3827
Product category
Ophthalmic Diagnostic Imaging Devices
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales
TypeHardware Sales
Description

Sale of FDA 510(k) cleared hyperspectral camera systems and associated AI-powered analytics software to eye care specialists and healthcare providers for clinical decision support in AMD diagnosis and management.

optina.net
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Optina Diagnostics develops an FDA 510(k) cleared hyperspectral retinal camera combined with AI-driven clinical decision analytics to enable eye care specialists to detect, identify, monitor, and manage Age-Related Macular Degeneration (AMD) in early, intermediate, and late stages. The platform captures hyperspectral retinal images in approximately one second and uses AI algorithms to support faster diagnosis, identify high-risk patients before vision loss occurs, and monitor therapeutic effectiveness in at-risk patients.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • ~1-second scan time for early and intermediate stage retinal disease detection
Product overview1 text field

Optina Diagnostics offers a unified Clinical Decision Analytics Platform built around an FDA 510(k)-cleared hyperspectral camera integrated with AI capabilities. The platform enables eye specialists to detect, identify, monitor, and enable rapid diagnosis and management of Age-Related Macular Degeneration across early, intermediate, and late stages. The core offering combines hardware (hyperspectral camera) with AI-driven software analysis to support clinical decision-making.

Product and service1 record
1Clinical Decision Analytics Platform
CategoryOphthalmic Diagnostic Imaging Devices
Description

AI-driven retinal imaging platform that supports faster and more effective diagnosis and management of patients with Age-Related Macular Degeneration through clinical decision support capabilities, enabling detection, identification, monitoring, and patient-centric care across early, intermediate, and late stages of retinal disease.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Developer of ultra-widefield retinal imaging devices (optomap) widely used in eye care practices for AMD and retinal disease screening. Directly competes for the same clinical workflow with hyperspectral/oct imaging alternatives.

TypeDirect peer
Description

Specialist in OCT, confocal laser ophthalmoscopy, and retinal imaging diagnostics used in AMD management. Closely comparable product portfolio and customer base of ophthalmologists and retina specialists.

TypeEmerging player
Description

AI-based retinal analysis platform for primary care and screening settings with FDA clearance for diabetic retinopathy. Comparable as a retinal AI diagnostics competitor targeting similar screening economics.

TypeEmerging player
Description

AI diagnostics company with FDA-authorized autonomous diagnostic system (IDx-DR) for diabetic retinopathy. Comparable as an emerging AI retinal diagnostics vendor with regulatory clearance and enterprise clinical channel.

5Carl Zeiss Meditec
TypeBroad incumbent
Description

Global leader in ophthalmic diagnostic and surgical devices, including OCT and fundus imaging systems. Directly comparable as an established retinal imaging incumbent competing for the same eye care specialist customers.

TypeBroad incumbent
Description

Japanese manufacturer of ophthalmic diagnostic equipment including retinal cameras and OCT systems. Sells into the same ophthalmology and optometry customer base with overlapping retinal imaging use cases.

TypeEmerging player
Description

Canadian AI-retinal-imaging company developing non-invasive Alzheimer's detection from retinal biomarkers. Closely comparable to Optina's cerebral amyloid/Alzheimer's application using hyperspectral retinal imaging.

TypeEmerging player
Description

AI retinal imaging company with FDA-cleared EyeArt system for autonomous diabetic retinopathy detection. Comparable AI-on-retinal-imaging business model targeting clinical screening workflows.

TypeBroad incumbent
Description

Major ophthalmic device manufacturer offering OCT, fundus cameras, and AI-enabled screening solutions (including Maestrocare and Harmony). Comparable as a full-portfolio retinal imaging and AI diagnostics vendor.

TypeDirect peer
Description

Manufacturer of fundus cameras and OCT systems (Eidon, Maestro) used in retinal disease screening including AMD. Directly competes in the ophthalmic imaging device category targeted at optometrists and ophthalmologists.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors16 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Optina Diagnostics

Ophthalmic Diagnostic Imaging Devicesoptinadx.com

Optina Diagnostics is a Montreal-based medical device company that combines an FDA 510(k)-cleared hyperspectral retinal camera with AI clinical decision analytics to support early detection and management of Age-Related Macular Degeneration, selling to ophthalmologists and retina specialists.

What Optina Diagnostics does

Optina Diagnostics is a Montreal-based private medical device and diagnostics company developing AI-enabled hyperspectral retinal imaging technology for early detection and management of retinal disease, with a primary focus on Age-Related Macular Degeneration (AMD). Its core offering combines an FDA 510(k)-cleared hyperspectral camera, which captures retinal images in approximately one second, with AI-driven clinical decision analytics designed to detect early and intermediate stage retinal disease, identify patients at high risk of vision impairment, and monitor disease progression and therapeutic response. The company is also extending the platform toward a cerebral amyloid status test for Alzheimer's detection, supported by a grant from the Alzheimer's Drug Discovery Foundation's Diagnostics Accelerator.

Optina sells its hardware-and-software platform through enterprise direct sales to eye care specialists, including ophthalmologists and retina specialists, primarily in the United States, Canada, and Europe, where it is expanding clinical study sites. The revenue model is hardware-centric, anchored on sales of the FDA-cleared camera system bundled with AI analytics software, though pricing is not publicly disclosed and operates on custom quotes. The company is venture capital-backed, having closed a CA$24.8 million Series A in October 2021 led by DigitalDx Ventures with participation from Boehringer Ingelheim Venture Fund, supplementing earlier seed and pre-seed rounds from Canadian and US investors.

The company operates in a large and growing addressable market: an estimated 300 million people are projected to experience moderate to severe vision loss from AMD by 2040, with annual direct healthcare costs of approximately US$100 billion in the US and US$343 billion globally. Optina is led by CEO David Lapointe and co-founder and CFO Chantal Miklosi, with a team in the 11-50 employee range, consistent with a clinical-stage medical device company still building toward scaled commercial deployment.

Optina Diagnostics firmographics

Firmographics
Name
Optina Diagnostics
Legal name
Optina
Website
https://optinadx.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
11–50 employees
Short description
Optina Diagnostics is a Montreal-based medical device company that combines an FDA 510(k)-cleared hyperspectral retinal camera with AI clinical decision analytics to support early detection and management of Age-Related Macular Degeneration, selling to ophthalmologists and retina specialists.
Ownership category
akta.pro rank

Optina Diagnostics industry classification

Industry
Product category
Ophthalmic Diagnostic Imaging Devices
NAICS
Ophthalmic Goods Manufacturing (339115)
SIC
Optical Instruments & Lenses (3827)
akta.pro industry
PRIMARYHLAHAJAB
Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAKAKAE
Retina & Vitreous Specialists

Keywords

  • Retinal imaging diagnostics
  • Hyperspectral imaging devices
  • AI clinical decision support
  • Ophthalmic medical devices
  • Macular degeneration detection

Where Optina Diagnostics is headquartered

Location

Headquarters

HQ city
Montréal
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

Optina Diagnostics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Medical Device Sales: Sale of FDA 510(k) cleared hyperspectral camera systems and associated AI-powered analytics software to eye care specialists and healthcare providers for clinical decision support in AMD diagnosis and management.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Optina Diagnostics product offering

Product offering

Core offering

Optina Diagnostics develops an FDA 510(k) cleared hyperspectral retinal camera combined with AI-driven clinical decision analytics to enable eye care specialists to detect, identify, monitor, and manage Age-Related Macular Degeneration (AMD) in early, intermediate, and late stages. The platform captures hyperspectral retinal images in approximately one second and uses AI algorithms to support faster diagnosis, identify high-risk patients before vision loss occurs, and monitor therapeutic effectiveness in at-risk patients.

Product overview

Optina Diagnostics offers a unified Clinical Decision Analytics Platform built around an FDA 510(k)-cleared hyperspectral camera integrated with AI capabilities. The platform enables eye specialists to detect, identify, monitor, and enable rapid diagnosis and management of Age-Related Macular Degeneration across early, intermediate, and late stages. The core offering combines hardware (hyperspectral camera) with AI-driven software analysis to support clinical decision-making.

Differentiator

Problem solved

Functional benefit

Products and services

  • Clinical Decision Analytics Platform AI-driven retinal imaging platform that supports faster and more effective diagnosis and management of patients with Age-Related Macular Degeneration through clinical decision support capabilities, enabling detection, identification, monitoring, and patient-centric care across early, intermediate, and late stages of retinal disease.

Quantifiable outcome

  • ~1-second scan time for early and intermediate stage retinal disease detection

Companies that use Optina Diagnostics

Customer profile

Segments1 record

Ideal customer profiles1 record

Optina Diagnostics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature2 records

Optina Diagnostics partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Optina Diagnostics competitors and assessment

Company assessment

Direct peers

  • Optos (Nikon): Developer of ultra-widefield retinal imaging devices (optomap) widely used in eye care practices for AMD and retinal disease screening. Directly competes for the same clinical workflow with hyperspectral/oct imaging alternatives.
  • Heidelberg Engineering: Specialist in OCT, confocal laser ophthalmoscopy, and retinal imaging diagnostics used in AMD management. Closely comparable product portfolio and customer base of ophthalmologists and retina specialists.
  • Centervue (iCare): Manufacturer of fundus cameras and OCT systems (Eidon, Maestro) used in retinal disease screening including AMD. Directly competes in the ophthalmic imaging device category targeted at optometrists and ophthalmologists.

Emerging players

  • AEYE Health: AI-based retinal analysis platform for primary care and screening settings with FDA clearance for diabetic retinopathy. Comparable as a retinal AI diagnostics competitor targeting similar screening economics.
  • Digital Diagnostics: AI diagnostics company with FDA-authorized autonomous diagnostic system (IDx-DR) for diabetic retinopathy. Comparable as an emerging AI retinal diagnostics vendor with regulatory clearance and enterprise clinical channel.
  • RetiSpec: Canadian AI-retinal-imaging company developing non-invasive Alzheimer's detection from retinal biomarkers. Closely comparable to Optina's cerebral amyloid/Alzheimer's application using hyperspectral retinal imaging.
  • Eyenuk: AI retinal imaging company with FDA-cleared EyeArt system for autonomous diabetic retinopathy detection. Comparable AI-on-retinal-imaging business model targeting clinical screening workflows.

Broad incumbents

  • Carl Zeiss Meditec: Global leader in ophthalmic diagnostic and surgical devices, including OCT and fundus imaging systems. Directly comparable as an established retinal imaging incumbent competing for the same eye care specialist customers.
  • Nidek: Japanese manufacturer of ophthalmic diagnostic equipment including retinal cameras and OCT systems. Sells into the same ophthalmology and optometry customer base with overlapping retinal imaging use cases.
  • Topcon Healthcare: Major ophthalmic device manufacturer offering OCT, fundus cameras, and AI-enabled screening solutions (including Maestrocare and Harmony). Comparable as a full-portfolio retinal imaging and AI diagnostics vendor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Optina Diagnostics social profiles

Digital presence

Optina Diagnostics compliance and trust

Trust signal

Compliance1 record

Optina Diagnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Optina Diagnostics leadership team

Management profile

Number of profiles

Profiles2 records

Optina Diagnostics funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Optina Diagnostics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Optina Diagnostics

What does Optina Diagnostics do?

Optina Diagnostics develops an FDA 510(k) cleared hyperspectral retinal camera combined with AI-driven clinical decision analytics to enable eye care specialists to detect, identify, monitor, and manage Age-Related Macular Degeneration (AMD) in early, intermediate, and late stages. The platform captures hyperspectral retinal images in approximately one second and uses AI algorithms to support faster diagnosis, identify high-risk patients before vision loss occurs, and monitor therapeutic effectiveness in at-risk patients.

Is Optina Diagnostics a public or private company?

Optina Diagnostics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Optina Diagnostics founded?

Optina Diagnostics was founded in 2011. It employs 11 to 50 people.

Where is Optina Diagnostics based?

Optina Diagnostics is headquartered in Montréal, Canada, in the North America region.

How does Optina Diagnostics make money?

One revenue line is on record: medical Device Sales.

Who are Optina Diagnostics's main competitors?

Direct peers on record are Optos (Nikon), Heidelberg Engineering and Centervue (iCare). Emerging players are AEYE Health, Digital Diagnostics, RetiSpec and Eyenuk. Broad incumbents are Carl Zeiss Meditec, Nidek and Topcon Healthcare.

Does Optina Diagnostics have an API?

No public API is recorded for Optina Diagnostics.

What industry is Optina Diagnostics in?

Optina Diagnostics's product category is Ophthalmic Diagnostic Imaging Devices. Its primary akta.pro industry code is HLAHAJAB, Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography), with a secondary code of HLAKAKAE, Retina & Vitreous Specialists. Its NAICS code is 339115 and its SIC code is 3827.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireOptina's Landmark REPHRASE Study to Validate an Innovative Cerebral Amyloid Status Test for the Diagnosis and Management of Alzheimer's DiseaseOptina Diagnostics is conducting the REPHRASE study to validate its awAIr-Cerebral Amyloid Status test for Alzheimer's diagnosis. The non-invasive retinal scan test, with FDA Breakthrough Device designation, aims to enable earlier detection and treatment. The study, funded by the Alzheimer's Drug Discovery Foundation, is expected to complete by Q4 2023.PR NewswireOptina Diagnostics Earns Frost & Sullivan's 2022 North American Technology Innovation Leadership Award for Leveraging Innovative Eye Imagery and Artificial Intelligence for Chronic Diseases DetectionFrost & Sullivan has awarded Optina Diagnostics the 2022 Technology Innovation Leadership Award for its AI-powered Retinal Deep Phenotyping™ solutions, specifically the Optina-4C™ hyperspectral retinal imaging camera. The company is developing the awAIr™ cerebral amyloid status test for early and non-invasive detection of Alzheimer's disease and is partnering with pharmaceutical companies to advance new studies and biomarkers for chronic disease diagnostics. Frost & Sullivan recognized the technology as potentially disruptive for enabling early-stage diagnosis of multiple systemic diseases through accessible retinal imaging.Medical Tech OutlookTop Emerging Neurology Device Providers 2020Optina Diagnostics was named a Top 10 Emerging Neurology Device Provider by MedTech Outlook for its retinal scan platform that detects early Alzheimer's signs. The platform uses hyper-spectral imaging to capture over 100 eye images in under a second, targeting B-amyloid and atherosclerosis. Clinical trials are ongoing in the U.S., Canada, and Australia, with expansion planned for Japan and Europe.BetaKitOptina secures up to $2.6 million from Bill Gates, Jeff Bezos-backed foundation for Alzheimer’s discoveryOptina Diagnostics will receive up to $2.6 million CAD from the Alzheimer's Drug Discovery Foundation to expand its clinical study sites. The funding supports the awAIr cerebral amyloid test's FDA regulatory submission, with the study across five sites in the US, Canada, and Europe.YahooDIAGNOS Provides Corporate Update for 2021 and Outlook for 2022DIAGNOS reported its 2021 corporate update, highlighting a stroke-detection clinical trial with CommonSpirit Health and a three-year contract renewal with Optina Diagnostics. The company also signed an MoU with Essilor International and opened five screening clinics in Saudi Arabia. It expects to become cashflow positive by June 2022.GlobeNewswireDIAGNOS Provides Corporate Update for 2021 and Outlook for 2022DIAGNOS reported its 2021 corporate update, highlighting a stroke-detection clinical trial with CommonSpirit Health and a contract renewal with Optina Diagnostics. The company also signed an MoU with Essilor International and opened five screening clinics in Saudi Arabia. It expects to become cashflow positive by the end of June 2022.FinSMEsOptina Raises US$2.1M in FundingOptina, a Montreal-based diagnostics company, closed an up to US$2.1M funding round led by DigitalDx Ventures. The funds will support its pivotal study for the awAIrTM cerebral amyloid status test, expanding the cohort across 5 sites in the US, Canada, and Europe.PR NewswireOptina announces a US$2.1M investment from the Diagnostics Accelerator at the Alzheimer's Drug Discovery Foundation (ADDF)Optina closed a US$2.1M investment from the Alzheimer's Drug Discovery Foundation's Diagnostics Accelerator. The funding will support its pivotal study for the awAIr cerebral amyloid status test, expanding the cohort across 5 sites in the US, Canada, and Europe. The company also plans to deploy additional clinical study sites.BioSpaceOptina announces a US$2.1M investment from the Diagnostics Accelerator at the Alzheimer’s Drug Discovery Foundation (ADDF)Optina announced the closing of a US$2.1 million investment from the Alzheimer's Drug Discovery Foundation (ADDF) to support its pivotal study for an FDA regulatory submission regarding an AI-based cerebral amyloid status test for Alzheimer's disease. This funding follows an oversubscribed Series-A round led by DigitalDx Ventures and will enable Optina to expand its clinical study cohort across sites in the USA, Canada, and Europe. The investment aims to accelerate the deployment of Optina's Retinal Deep Phenotyping platform to improve early, non-invasive detection of Alzheimer's.InvestorintelThe EYES have it, Early Stage Detection of Diabetes and Cardiovascular DiseaseDIAGNOS is developing an AI-based retinal screening platform to detect early diabetes and cardiovascular disease, with USA clinical trials starting December 2021. The company has cleared its CARA technology in multiple jurisdictions and operates in 16 countries with over 400,000 retinographies performed.